CorMedix (CRMD) Research & Development (2016 - 2025)
CorMedix has reported Research & Development over the past 15 years, most recently at $8.6 million for Q4 2025.
- Quarterly results put Research & Development at $8.6 million for Q4 2025, up 398.14% from a year ago — trailing twelve months through Dec 2025 was $19.3 million (up 390.44% YoY), and the annual figure for FY2025 was $19.3 million, up 390.44%.
- Research & Development reached $8.6 million in Q4 2025 per CRMD's latest filing, up from $5.1 million in the prior quarter.
- Across five years, Research & Development topped out at $8.6 million in Q4 2025 and bottomed at $650988.0 in Q2 2024.
- Median Research & Development over the past 5 years was $2.7 million (2021), compared with a mean of $3.0 million.
- The largest annual shift saw Research & Development plummeted 86.42% in 2024 before it surged 601.07% in 2025.
- Over 5 years, Research & Development stood at $3.2 million in 2021, then decreased by 12.12% to $2.8 million in 2022, then fell by 19.5% to $2.3 million in 2023, then decreased by 24.57% to $1.7 million in 2024, then soared by 398.14% to $8.6 million in 2025.
- Business Quant data shows Research & Development for CRMD at $8.6 million in Q4 2025, $5.1 million in Q3 2025, and $2.4 million in Q2 2025.